INDV vs. RDY, ASND, VTRS, ROIV, QGEN, ELAN, BBIO, MRNA, VRNA, and RVMD
Should you be buying Indivior stock or one of its competitors? The main competitors of Indivior include Dr. Reddy's Laboratories (RDY), Ascendis Pharma A/S (ASND), Viatris (VTRS), Roivant Sciences (ROIV), QIAGEN (QGEN), Elanco Animal Health (ELAN), BridgeBio Pharma (BBIO), Moderna (MRNA), Verona Pharma PLC American Depositary Share (VRNA), and Revolution Medicines (RVMD). These companies are all part of the "pharmaceutical products" industry.
Indivior vs. Its Competitors
Indivior (NASDAQ:INDV) and Dr. Reddy's Laboratories (NYSE:RDY) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, dividends, earnings, profitability, valuation and institutional ownership.
60.3% of Indivior shares are owned by institutional investors. Comparatively, 3.8% of Dr. Reddy's Laboratories shares are owned by institutional investors. 2.0% of Dr. Reddy's Laboratories shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Dr. Reddy's Laboratories has a net margin of 16.99% compared to Indivior's net margin of 6.65%. Dr. Reddy's Laboratories' return on equity of 17.25% beat Indivior's return on equity.
Dr. Reddy's Laboratories has higher revenue and earnings than Indivior. Dr. Reddy's Laboratories is trading at a lower price-to-earnings ratio than Indivior, indicating that it is currently the more affordable of the two stocks.
In the previous week, Indivior had 1 more articles in the media than Dr. Reddy's Laboratories. MarketBeat recorded 2 mentions for Indivior and 1 mentions for Dr. Reddy's Laboratories. Dr. Reddy's Laboratories' average media sentiment score of 1.86 beat Indivior's score of 0.42 indicating that Dr. Reddy's Laboratories is being referred to more favorably in the news media.
Indivior currently has a consensus target price of $22.00, indicating a potential downside of 3.78%. Dr. Reddy's Laboratories has a consensus target price of $16.95, indicating a potential upside of 20.00%. Given Dr. Reddy's Laboratories' higher possible upside, analysts clearly believe Dr. Reddy's Laboratories is more favorable than Indivior.
Indivior has a beta of 0.7, suggesting that its share price is 30% less volatile than the S&P 500. Comparatively, Dr. Reddy's Laboratories has a beta of 0.4, suggesting that its share price is 60% less volatile than the S&P 500.
Summary
Indivior and Dr. Reddy's Laboratories tied by winning 8 of the 16 factors compared between the two stocks.
Get Indivior News Delivered to You Automatically
Sign up to receive the latest news and ratings for INDV and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding INDV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Indivior Competitors List
Related Companies and Tools
This page (NASDAQ:INDV) was last updated on 10/6/2025 by MarketBeat.com Staff
